JPH07504203A - 腫瘍壊死因子アンタゴニストを用いるｔｎｆ−依存性炎症の治療方法 - Google Patents

腫瘍壊死因子アンタゴニストを用いるｔｎｆ−依存性炎症の治療方法

Info

Publication number
JPH07504203A
JPH07504203A JP6508252A JP50825294A JPH07504203A JP H07504203 A JPH07504203 A JP H07504203A JP 6508252 A JP6508252 A JP 6508252A JP 50825294 A JP50825294 A JP 50825294A JP H07504203 A JPH07504203 A JP H07504203A
Authority
JP
Japan
Prior art keywords
tnfr
tnf
sequence
soluble
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP6508252A
Other languages
English (en)
Japanese (ja)
Inventor
スミス，クレイグ・エイ
ヤコブス，シンディー・エイ
Original Assignee
イミュネックス・コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25484181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH07504203(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by イミュネックス・コーポレーション filed Critical イミュネックス・コーポレーション
Publication of JPH07504203A publication Critical patent/JPH07504203A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP6508252A 1992-09-15 1993-09-14 腫瘍壊死因子アンタゴニストを用いるｔｎｆ−依存性炎症の治療方法 Pending JPH07504203A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US946,236 1978-09-27
US94623692A 1992-09-15 1992-09-15
PCT/US1993/008666 WO1994006476A1 (en) 1992-09-15 1993-09-14 Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists

Publications (1)

Publication Number Publication Date
JPH07504203A true JPH07504203A (ja) 1995-05-11

Family

ID=25484181

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6508252A Pending JPH07504203A (ja) 1992-09-15 1993-09-14 腫瘍壊死因子アンタゴニストを用いるｔｎｆ−依存性炎症の治療方法

Country Status (8)

Country Link
EP (1) EP0620739A4 (no)
JP (1) JPH07504203A (no)
KR (1) KR100232688B1 (no)
AU (1) AU670125B2 (no)
CA (1) CA2123593C (no)
NO (1) NO941780L (no)
NZ (1) NZ256293A (no)
WO (1) WO1994006476A1 (no)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002534375A (ja) * 1998-12-30 2002-10-15 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ 活性阻害
JP2003501043A (ja) * 1999-05-28 2003-01-14 ターゲティッド ジェネティクス コーポレイション 腫瘍壊死因子（ｔｎｆ）関連障害において、ｔｎｆのレベルを低下させるための方法および組成物
JP2006500927A (ja) * 2002-09-13 2006-01-12 ザ・ユニバーシティ・オブ・クイーンズランド コドン翻訳効率に基づく遺伝子発現系
JP2006512900A (ja) * 2002-08-16 2006-04-20 ワイス Ｒａｇｅ関連疾患の治療用組成物及び方法
JP2007084558A (ja) * 1998-10-23 2007-04-05 Amgen 治療薬としての修飾ペプチド
US7229962B2 (en) 2001-07-26 2007-06-12 Medexgen Co., Ltd. Tetravalent etanercept
JPWO2005035586A1 (ja) * 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
JP2010501622A (ja) * 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Ｆｃ−融合タンパク質の精製法

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0393438B1 (de) 1989-04-21 2005-02-16 Amgen Inc. TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
EP0670730B1 (en) * 1992-03-30 2003-06-04 Immunex Corporation Fusion protein comprising two tumor necrosis factor receptors
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
BR9508419A (pt) * 1994-07-22 1997-11-18 Hoffmann La Roche Composições farmacêuticas compreendendo uma proteina de ligação de tnf quinerica
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
AU4658596A (en) * 1995-02-03 1996-08-21 G.D. Searle & Co. Novel c-mpl ligands
IL112834A (en) * 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
ATE212231T1 (de) * 1995-07-14 2002-02-15 Applied Research Systems Tnf-rezeptor und steroidhormon dhea in einer kombinationstherapie
US7012060B1 (en) 1995-07-14 2006-03-14 Applied Research Systems Ars Holding N.V. TNF receptor and steroid hormone in a combined therapy
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
JP2000510113A (ja) * 1996-05-08 2000-08-08 エフ・ホフマン―ラ ロシュ アーゲー ＴＮＦＲ―Ｉｇによる喘息の治療
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
CA2273850A1 (en) 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
EP1352656A3 (en) * 1996-12-06 2004-02-04 Amgen Inc. Combination therapy using a TNF binding protein for treating TNF-mediated diseases
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
EP1170017A1 (en) * 1997-05-12 2002-01-09 The Kennedy Institute Of Rheumatology Use of tumor necrosis factor alpha (TNF-alpha) and vascular endothelial growth factor (VEGF) for the manufacture of a therapeutic composition
AU8408798A (en) * 1997-07-17 1999-02-10 Regents Of The University Of Michigan, The Methods and compositions for inhibiting the proinflammatory response
WO2000002902A1 (en) * 1998-07-13 2000-01-20 Gill Parkash S Novel inhibitors of angiogenesis and tumor growth
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
AU1345000A (en) * 1998-11-05 2000-05-22 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
EP1022027A1 (en) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Tumor necrosis factor antagonists and their use in endometriosis
AU763575B2 (en) * 1999-04-02 2003-07-24 Immunex Corporation Use of soluble tumor necrosis factor receptor for treatment heart failure
EP1939300A1 (en) * 1999-05-28 2008-07-02 Targeted Genetics Corporation Methods and compositions for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
US6627199B1 (en) 1999-07-09 2003-09-30 Amgen Inc Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family
ES2308985T3 (es) * 1999-07-21 2008-12-16 Omeros Corporation Disoluciones y procedimientos para la inhibicion del dolor, inflamacion y degradacion del cartilago.
AU6517800A (en) 1999-08-04 2001-03-05 Amgen, Inc. Ntr3, a member of the tnf-receptor supergene family
AU783682B2 (en) 1999-08-04 2005-11-24 Amgen, Inc. Fhm, a novel member of the TNF ligand supergene family
GB9927681D0 (en) * 1999-11-23 2000-01-19 Glaxo Group Ltd Protein
KR20020097241A (ko) 2000-05-04 2002-12-31 에이브이아이 바이오파마 인코포레이티드 스플라이스-영역 안티센스 조성물 및 방법
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040126372A1 (en) 2002-07-19 2004-07-01 Abbott Biotechnology Ltd. Treatment of TNFalpha related disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
DE602004013557D1 (de) * 2003-02-28 2008-06-19 Ares Trading Sa FLÜSSIGE FORMULIERUNGEN DES TUMORNEKROSEFRAKTOR-BINDUNGSPROTEINs TBP-1
TWI556829B (zh) 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
EP2332985A3 (en) * 2004-11-12 2012-01-25 Xencor, Inc. Fc variants with altered binding to FcRn
AU2006230419A1 (en) * 2005-03-31 2006-10-05 Targeted Genetics Corporation Methods for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
NZ591701A (en) 2005-05-16 2012-11-30 Abbott Biotech Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
RU2438704C2 (ru) 2005-11-01 2012-01-10 Эбботт Байотекнолоджи Лтд. Способы и композиции для диагностики анкилозирующих спондилитов с использованием биомаркеров
US7785834B2 (en) 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
US7972599B2 (en) 2006-03-20 2011-07-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Immunomodulation of inflammatory conditions utilizing Follistatin-like protein-1 and agents that bind thereto
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
TWI392684B (zh) 2006-04-05 2013-04-11 Abbott Biotech Ltd 抗體之純化
WO2008063213A2 (en) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
EP2708242A3 (en) 2006-04-10 2014-03-26 Abbott Biotechnology Ltd Uses and compositions for treatment of ankylosing spondylitis
CA2564435A1 (en) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
TWI527603B (zh) 2006-06-30 2016-04-01 艾伯維生物技術有限責任公司 自動注射裝置
JP2010501623A (ja) 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Ｆｃ含有タンパク質の精製法
EA017733B1 (ru) * 2006-08-28 2013-02-28 Арес Трейдинг С.А. СПОСОБ ОЧИСТКИ Fc-СЛИТЫХ БЕЛКОВ
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
EP2311481A3 (en) 2006-10-20 2013-10-16 Biogen Idec MA Inc. Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
CA2666981A1 (en) * 2006-10-20 2008-05-02 Ercole Biotech, Inc. Soluble tnf receptors and their use in treatment of disease
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
EP2165194A4 (en) 2007-05-31 2010-09-08 Abbott Lab BIOMARKERS FOR PREDICTING RESPONSABILITY TO TNF ALPHA INHIBITORS IN AUTOIMMUNE DISEASES
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
RU2513695C2 (ru) 2007-06-14 2014-04-20 Гэлэктика Фармасьютикалс, Инк. Слитые белки rage
EP2072527A1 (en) 2007-12-21 2009-06-24 Altonabiotec AG Fusion polypeptides comprising a SHBG dimerization component and uses thereof
US8658379B2 (en) 2008-01-29 2014-02-25 University of Pittsburgh—of the Commonwealth System of Higher Education Follistatin-like protein-1 as a biomarker for sepsis
MX2011001644A (es) * 2008-08-12 2011-10-06 Avesthagen Ltd Un vector de expresion y un metodo del mismo.
AU2009333489A1 (en) 2008-12-30 2010-07-08 Centocor Ortho Biotech Inc. Serum markers predicting clinical response to anti-TNF antibodies in patients with ankylosing spondylitis
MX2011011541A (es) 2009-04-29 2012-02-28 Abbott Biotech Ltd Dispositivo de inyeccion automatico.
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
BR112012013330A2 (pt) 2009-12-02 2017-03-28 Acceleron Pharma Inc composições e métodos para aumentar meia vida do soro de proteínas de fusão fc
US20110150891A1 (en) 2009-12-16 2011-06-23 Philip Bosch Methods of Treating Interstitial Cystitis
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
SG182468A1 (en) 2010-01-15 2012-08-30 Kirin Amgen Inc Antibody formulation and therapeutic regimens
EP2531613A2 (en) 2010-02-02 2012-12-12 Abbott Biotechnology Ltd. Methods and compositions for predicting responsiveness to treatment with tnf-alpha inhibitor
CN104906656B (zh) 2010-04-21 2020-01-10 艾伯维生物技术有限公司 用于治疗药剂的受控输送的可佩戴自动注射装置
WO2011146727A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of treating interstitial cystitis
CN105056232A (zh) 2010-06-03 2015-11-18 阿布维生物技术有限公司 用于治疗化脓性汗腺炎(hs)的用途和组合物
FR2962335B1 (fr) 2010-07-12 2013-01-18 Cll Pharma Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives
WO2012019099A2 (en) 2010-08-05 2012-02-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Follistatin-like-protein-1 as a biomarker for inflammatory disorders
EP2667918B1 (en) 2011-01-24 2017-03-01 AbbVie Biotechnology Ltd Automatic injection devices having overmolded gripping surfaces
JP2014511711A (ja) 2011-03-18 2014-05-19 アッヴィ・インコーポレイテッド 自動注入デバイスおよびそのサブアセンブリを組み立てるためのシステム、デバイス、および方法
ES2669198T5 (es) 2011-03-29 2021-07-20 Abbvie Inc Despliegue de envolvente mejorado en dispositivos de inyección automáticos
CN107096098A (zh) 2011-04-21 2017-08-29 艾伯维公司 可佩戴式自动注射装置
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
US8883982B2 (en) 2011-06-08 2014-11-11 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
JP6220789B2 (ja) 2011-10-18 2017-10-25 コヒラス・バイオサイエンシズ・インコーポレイテッド 糖およびポリオールの組合せによって安定化されたエタネルセプト製剤
KR101525919B1 (ko) * 2012-05-11 2015-06-03 가톨릭대학교 산학협력단 자가면역 질환 예방 및 치료를 위한 ｔｎｆｒ２를 기반으로 하는 이중 항체
CN104902914B (zh) 2012-09-11 2019-01-01 科荣生生物科学公司 高纯度和优异产量的正确折叠的依那西普
JP6596014B2 (ja) 2014-03-31 2019-10-23 アムジェン ケー・エー，インコーポレイテッド 爪および頭皮乾癬の治療方法
WO2015198320A1 (en) 2014-06-24 2015-12-30 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
EP3236990B1 (en) 2014-12-22 2020-09-02 Ares Trading S.A. Liquid pharmaceutical composition
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
AU2017248354A1 (en) 2016-04-08 2018-10-04 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
EP3257866A1 (en) 2016-06-17 2017-12-20 Academisch Medisch Centrum Modified anti-tnf antibody and use thereof in the treatment of ibd
EP3554342A1 (en) 2016-12-14 2019-10-23 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
JOP20190162A1 (ar) 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
US20230312700A1 (en) 2018-06-20 2023-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
WO2020010118A1 (en) 2018-07-03 2020-01-09 Novartis Inflammasome Research, Inc. Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist
JP2022502350A (ja) 2018-08-29 2022-01-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. 関節リウマチを有する対象を治療するための方法および組成物
CN114206442A (zh) 2019-01-31 2022-03-18 赛诺菲生物技术公司 用于治疗幼年特发性关节炎的抗il-6受体抗体
CN110964119A (zh) * 2019-12-05 2020-04-07 沣潮医药科技（上海）有限公司 抗疟二聚体免疫粘附素、药物组合物和用途
WO2022123293A1 (ko) 2020-12-09 2022-06-16 에이치케이이노엔 주식회사 항 OX40L 항체, 항 OX40L 및 항 TNFα 이중 특이성 항체 및 이들의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
WO1991003553A1 (en) * 1989-09-05 1991-03-21 Immunex Corporation TUMOR NECROSIS FACTOR-α AND -β RECEPTORS
JP2864434B2 (ja) * 1991-01-18 1999-03-03 サイナーゲン，インコーポレーテッド 腫瘍壊死因子媒介疾患の治療方法
CA2145192A1 (en) * 1992-09-22 1994-03-31 Gail Underiner Novel epoxide-containing compounds

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007084558A (ja) * 1998-10-23 2007-04-05 Amgen 治療薬としての修飾ペプチド
JP2002534375A (ja) * 1998-12-30 2002-10-15 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ 活性阻害
JP2003501043A (ja) * 1999-05-28 2003-01-14 ターゲティッド ジェネティクス コーポレイション 腫瘍壊死因子（ｔｎｆ）関連障害において、ｔｎｆのレベルを低下させるための方法および組成物
US7229962B2 (en) 2001-07-26 2007-06-12 Medexgen Co., Ltd. Tetravalent etanercept
US7670602B2 (en) 2001-07-26 2010-03-02 Medexgen Co., Ltd Concatameric immunoadhesion molecule
US8372961B2 (en) 2001-07-26 2013-02-12 Medexgen Co., Ltd. Polynucleotides encoding concatameric immunoadhesion molecules
JP2006512900A (ja) * 2002-08-16 2006-04-20 ワイス Ｒａｇｅ関連疾患の治療用組成物及び方法
JP2006500927A (ja) * 2002-09-13 2006-01-12 ザ・ユニバーシティ・オブ・クイーンズランド コドン翻訳効率に基づく遺伝子発現系
JPWO2005035586A1 (ja) * 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
JP2010501622A (ja) * 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Ｆｃ−融合タンパク質の精製法

Also Published As

Publication number Publication date
WO1994006476A1 (en) 1994-03-31
AU4920993A (en) 1994-04-12
NO941780D0 (no) 1994-05-11
EP0620739A4 (en) 1997-01-15
NZ256293A (en) 1997-06-24
KR100232688B1 (ko) 1999-12-01
CA2123593A1 (en) 1994-03-31
NO941780L (no) 1994-07-15
CA2123593C (en) 2000-03-14
EP0620739A1 (en) 1994-10-26
AU670125B2 (en) 1996-07-04

Similar Documents

Publication Publication Date Title
JPH07504203A (ja) 腫瘍壊死因子アンタゴニストを用いるｔｎｆ−依存性炎症の治療方法
US5605690A (en) Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
JP2721745B2 (ja) 腫瘍壊死因子―αおよび―βレセプター
ES2080809T4 (es) Receptores de factor de necrosis tumoral alfa y beta
CA2065346C (en) Tumor necrosis factor-.alpha. and-.beta. receptors
US8362206B2 (en) Chimeric proteins and uses thereof
US5945397A (en) Purified p75 (type II) tumor necrosis factor receptor polypeptides
JPS6140221A (ja) 腫瘍壊死因子
DE69535719T2 (de) Fas-antigenbindender ligand
JPH07508639A (ja) 腫瘍壊死因子受容体を含む融合蛋白質
JPH10502810A (ja) Ｌｅｒｋ−５と命名された新規のサイトカイン
JPH09505721A (ja) インターロイキン６レセプターアンタゴニスト
JPH11503309A (ja) Ｉｌ−１７受容体
AU8656991A (en) Isolated viral protein cytokine antagonists
JP2001506982A (ja) 一酸化窒素産生の制御法
US7700318B2 (en) Chimeric polypeptide and use thereof
WO2021142573A1 (zh) 一种融合蛋白及其制法和用途
WO2022188883A1 (zh) Tnfr2与april/baff受体的融合蛋白
FI108645B (fi) Kasvainkuoliotekijä-alfa- ja kasvainkuoliotekijä-beta- reseptoreita
US20050042228A1 (en) Method and pharmaceutical composition for the treatment of immune disorders
IE911108A1 (en) Isolated Viral Protein Cytokine Antagonists
DD297664A5 (de) Tumornekrose-faktor-alpha- und -beta-rezeptoren